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Mutations in Iron-Sulfur Cluster Scaffold Genes NFU1
and BOLA3 Cause a Fatal Deficiency of Multiple
Respiratory Chain and 2-Oxoacid Dehydrogenase Enzymes
Jessie M. Cameron,1,5 Alexandre Janer,2,5 Valeriy Levandovskiy,1 Nevena MacKay,1 Tracey A. Rouault,3
Wing-Hang Tong,3 Isla Ogilvie,2 Eric A. Shoubridge,2 and Brian H. Robinson1,4,*
Severe combined deficiency of the 2-oxoacid dehydrogenases, associated with a defect in lipoate synthesis and accompanied by defects
in complexes I, II, and III of the mitochondrial respiratory chain, is a rare autosomal recessive syndrome with no obvious causative gene
defect. A candidate locus for this syndrome was mapped to chromosomal region 2p14 by microcell-mediated chromosome transfer in
two unrelated families. Unexpectedly, analysis of genes in this area identified mutations in two different genes, both of which are
involved in [Fe-S] cluster biogenesis. A homozygous missense mutation, c.545G>A, near the splice donor of exon 6 in NFU1 predicting
a p.Arg182Gln substitution was found in one of the families. The mutation results in abnormal mRNA splicing of exon 6, and nomature
protein could be detected in fibroblast mitochondria. A single base-pair duplication c.123dupA was identified in BOLA3 in the second
family, causing a frame shift that produces a premature stop codon (p.Glu42Argfs*13). Transduction of fibroblast lines with retroviral
vectors expressing the mitochondrial, but not the cytosolic isoform of NFU1 and with isoform 1, but not isoform 2 of BOLA3 restored
both respiratory chain function and oxoacid dehydrogenase complexes. NFU1 was previously proposed to be an alternative scaffold to
ISCU for the biogenesis of [Fe-S] centers in mitochondria, and the function of BOLA3 was previously unknown. Our results demonstrate
that both play essential roles in the production of [Fe-S] centers for the normal maturation of lipoate-containing 2-oxoacid dehydroge-
nases, and for the assembly of the respiratory chain complexes.Introduction
Pyruvate dehydrogenase complex (PDHc) deficiency most
often occurs as an isolated enzyme defect caused by muta-
tions in X-linked PDHA1 (MIM 300502) and produces a
spectrum of clinical presentations ranging from fatal infan-
tile lactic acidosis to mild psychomotor retardation.1,2
A smaller number of PDHc deficient individuals have
mutations in PDHB (MIM 179060), PDHX (MIM 608769),
dihydrolipoyl transacetylase (DLAT, MIM 608770), dihy-
drolipoyl dehydrogenase (DLD, MIM 238331), or PDP1
(MIM 605993), which controls the reactivation of phos-
phorylated PDHc.3–5 We have described two unrelated
families with neonatal, severe deficiencies of PDHc associ-
ated with defects in oxoglutarate dehydrogenase complex
(OGDHc) andwith complexes I, II, and III of the respiratory
chain, and we called this multiple mitochondrial dysfunc-
tions syndrome (MIM 605711, Table 1). Using the tech-
nique of microcell-mediated chromosome transfer, we
defined a candidate locus on chromosome 2p14 for both
families.6 The locus covers 10 Mb of sequence in a region
containing more than 50 genes, many of which have no
defined function. We sequenced a number of genes as
candidates for this syndrome and focused on genes with
a high probability of targeting to the mitochondria (deter-
mined withMitoprot7). Twomitochondrial genes involved
in iron-sulfur ([Fe-S]) cluster assembly were likely candi-1Genetics and Genome Biology, The Research Institute, The Hospital for Sick C
McGill University and the Montreal Neurological Institute, Montreal, QC H
National Institute of Child Health and Human Development/National Instit
and Paediatrics, University of Toronto, 1 King’s College Circle, Toronto, ON M
5These authors contributed equally to this work
*Correspondence: bhr@sickkids.ca
DOI 10.1016/j.ajhg.2011.08.011. 2011 by The American Society of Human
486 The American Journal of Human Genetics 89, 486–495, Octoberdates for containing mutations that could cause the multi-
enzyme deficiency. This deduction was based on the
presence of [Fe-S] clusters in protein components of all
the affected respiratory chain enzyme complexes.
In this study, we show that two genes involved in the
biogenesis of [Fe-S] clusters have profound effects on the
respiratory chain and 2-oxoacid dehydrogenase complexes
(Figure 1).Materials and Methods
Families
Both families have been described in a previous publication.6
Briefly, the family with the NFU1mutation comprises two affected
males, one affected female, and one unaffected female (Figure 2).
The parents are nonconsanguineous and of Mexican descent.
The family with the BOLA3 mutation comprises one affected
male and one unaffected male (Figure 3). The parents are first
cousins and of East Indian descent. Enzymatic deficiencies of the
respiratory chain and 2-oxoacid dehydrogenases are summarized
in Table 1. All procedures were carried out with approval from
The Hospital for Sick Children’s research ethics board.
Cell Culture
Cultured skin fibroblasts were grown from forearm skin biopsy
(taken with informed consent) in a-MEM culture medium
(11mMglucose) and 20% fetal calf serum (Wisent, Saint-Jean-Bap-
tiste de Rouville, Quebec, Canada). Lymphoblasts were grown inhildren, Toronto, ONM5G 1X8, Canada; 2Department of Human Genetics,
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Complex I (IþIII) [2Fe-2S] (32), [4Fe-4S] (36) ~30% ~30% ~70%
Complex II [2Fe-2S], [3Fe-4S], [4Fe-4S] 50% 50% ~20%
Complex III [2Fe-2S] ~60% ~60% ~40%
Complex IV ~50% in 2 sibs,
normal in 1 sib
normal normal
Mitochondrial Aconitase [4Fe-4S] normal normal ~30%
PDHc requires covalently
attached lipoate on E2
~510% ~510% ND
E2 requires covalently
attached lipoate on E2,
but assay works with
added lipoic acid
normal ND ND
E3 normal ND ND
OGDHc lipoate requiring ~10% ~30% ND
ND is used as an abbreviation for not determined.10% fetal calf serum/RPMI. Primary human skin fibroblasts were
immortalized with a retrovirus expressing the E7 gene of type-16
human papilloma virus and a retroviral vector expressing the
protein component (htert) of human telomerase.8 These cells
were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum.
Molecular Genetic Techniques
Genomic DNA was isolated from fibroblasts or blood with the
Puregene genomic DNA isolation kit (Inter Medico). RNA was
isolated with Trizol, and full-length NFU1 cDNA sequence was
reverse transcribed with Superscript II reverse transcriptase and
amplified with Platinum Hi-Fi Taq polymerase (all from Invitro-
gen). Oligonucleotide primers used are shown in Table S1, avail-
able online. All PCR products were sequenced directly by fluores-
cent sequencing methods (ACGT Corporation, Toronto, Canada).
Retroviral vectors containing the HA-tagged cDNA sequence of
the cytosolic and mitochondrial versions of NFU1 and isoforms
1 and 2 of BOLA3 were created with the Gateway cloning system
(Invitrogen) as previously described.9 We amplified cDNAs from
these genes by using RNA isolated from fibroblasts with the
RNeasy kit (QIAGEN), by OneStep RT-PCR (QIAGEN) with specific
primers modified for cloning into Gateway vectors (flanked with
attB1 and attB2-HA sequences). The PCR constructs were cloned
into a Gateway-modified retroviral expression vector pLXSH.
The fidelity of cDNA clones was confirmed by automated DNA
sequencing. Retroviral constructs were used to transiently trans-
fect a Phoenix packaging cell line with the HBS/Ca3(PO4)2 method
(seeWeb Resources). Affected and control fibroblasts were infected
48 hr later by exposure to virus-containing medium in the pres-
ence of 4 mg/ml of polybrene.
Immunoblotting and Blue Native Gel Electrophoresis
For immunoblot analysis, fibroblasts were used to prepare mito-
chondria.10 twenty-five micrograms of mitochondria was resolved
through a 12.5% stacking SDS/PAGE gel. The SDS/PAGE gel was
electroblotted onto polyvinylidene fluoride membrane, blocked
with 5% skim milk/Tris buffered saline with Tween (TBST), andThe Americprobed with antibodies. Anti-human citrate synthase and anti-
holoCOX were prepared by immunizing rabbits with purified
citrate synthase or bovine heart cytochrome oxidase. The anti-
NFU1was a gift fromTracey Rouault, National Institutes of Health.
Antibodies to complex I subunits 75 kDa (NDUFS1), 51 kDa
(NDUFV1), and 49 kDa (NDUFS2) were prepared by immunizing
rabbits with protein peptides, and complex I 39 kDa (NDUFA9)
and ASHI (NDUFB8), complex II SDHA, complex III UQCRFS1,
and UQCRC1 antibodies were purchased from Mitosciences
(Eugene, OR, USA). CYTB antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Lipoate antibody was purchased
from Cedarlane (Burlington, ON, Canada) and anti-GAPDH from
Abcam (Cambridge, MA, USA). Immunoreactive proteins were
visualized with Western Lightning Chemiluminescence Reagent
Plus (PerkinElmer Life andAnalytical Sciences). Bluenative gel elec-
trophoresis was carried out as previously described.11 We carried
out densitometry measurements by using ImageJ software.12
Immunofluorescence
Cells were rinsed two times with PBS, fixed with PBS 4% PFA for
20min, and rinsed three times with PBS. Permeabilizationwas per-
formed with PBS 0.1% Triton for 15 min followed by three rinses
with PBS. Nonspecific antigenic sites were blocked with PBS 4%
BSA for 30 min, and primary antibody were applied in blocking
solution for 2 hr at room temperature. After three rinses in PBS,
secondary antibody in blocking solution was applied for 1 hr
and followed by three rinses with PBS. Nuclei were counterstained
with DAPI, and cover glasses were mounted in Fluoromount. The
following antibodies were used: rabbit anti-NFU1 (1:1000), mouse
anti-SDHA (1:1000), mouse anti-HA (1:5000), goat anti-mouse
Alexa488 (1:2000), goat anti-rabbit Alexa488 (1:2000), goat anti-
mouse Alexa594 (1:2000), and goat anti-mouse Alexa594 (1:2000).Results
In the locus defined by chromosome transfer at 2p14,
we searched for a gene that might have effects on bothan Journal of Human Genetics 89, 486–495, October 7, 2011 487
Figure 1. Proposed Scheme for the Interaction of Human [Fe-S] Genes within the Mitochondria
mNFS1 produces elemental sulfur from cysteine and makes it available to mISCU by interaction with this scaffold protein. LYRM4 is
required for stabilization of mNFS1. Fe is provided by the chaperone frataxin (FXN) through an interaction with LYRM4 and mISCU,
and [2Fe-2S] clusters are assembled upon each monomer of mISCU. These are then combined into [4Fe-4S] clusters. Ferredoxin provides
the necessary reducing agents for these reactions from electrons initially provided by ferredoxin reductase (not shown). Cochaperones
HSCB, HSPA9, and GLRX5 bind to ISCU and aid in the transfer of [2Fe-2S] clusters into recipient proteins. Only GLRX5 is required
as a chaperone for [4Fe-4S] transfer. BOLA3 possibly functions by interacting with GLRX5. ISCA1,2 and IBA57 are required for the
maturation of aconitase-like proteins and the catalytic activation of radical SAM enzymes (e.g., lipoic acid synthase). IND1 is
a complex-I-specific assembly factor. mNFU1 is thought to act as an alternate scaffold, possibly for the assembly of a subset of [Fe-S]
proteins.
The E3BP and E2 subunits have covalently bound lipoic acid, which requires a complex synthesis process involving transfer of an
octanoyl-ACP (derived from fatty acid biosynthesis) onto an apoprotein by LIPT2. LIAS catalyzes the lipoylation of the octanoylated
apo-protein by using SAM and sulfur (potentially produced by the action of mNFS1). Ferredoxin (FDX1) is thought to provide
the reducing power. ISCA1,2 and IBA57 are required for catalytic activation of LIAS. Lipoylated E2 is present as dihydrolipoamide
S-acetyltransferase (DLAT) in PDHc, dihydrolipoamide S-succinyltransferase (DLST) in OGDH and dihydrolipoamide branched chain
transacetylase (DBT) in BCKADHc. Lipoylated E3-binding protein is present in PDHc. Diseases associated with defective mammalian
proteins are noted in italics.2-oxoacid dehydrogenase complexes and respiratory chain
complexes. Because the metabolic pathways involving
[Fe-S] cluster assembly are a likely common cause for
such defects, we sequenced NFU1 (MIM 608100), an essen-
tial protein in one of the two pathways for [Fe-S] assembly
in both families (Figures 1 and 2A). [Fe-S] clusters function
as the prosthetic groups of many proteins essential for
intermediary metabolism and oxidative phosphorylation.
They are constructed and assembled into proteins in
a series of complex biochemical reactions that appear to
run in two parallel pathways (Figure 1). Both ISCU (MIM
611911) andNFU1 can assemble [2Fe-2S] and [4Fe-4S] clus-
ters, although only a human defect in ISCU has been noted488 The American Journal of Human Genetics 89, 486–495, Octoberbefore; this defect causes Swedish myopathy with exercise
intolerance (MIM 255125).13–15 In family 1, a homozygous
missense mutation, c.545G>A (p.Arg182Gln), was identi-
fied in exon 6 of NFU1 in the three affected siblings but
not in their unaffected sibling, P4 (II-4). The mutation
was not identified in seven different control samples or
in the expressed sequence tag (EST) database (99 NFU1
ESTs).
NFU1 has two isoforms generated by alternative splicing,
with specific subcellular localizations (Figure 2B).16 In
isoform 2 (NM_001002755.1), exon 1B, which contains
an in-frame stop codon, is spliced out, and the protein
is predicted to be targeted to mitochondria by a leader7, 2011
Figure 2. Analysis of NFU1 in Family 1
(A) Sequence chromatograms are shown
for gDNA regions of NFU1. The
c.545G>A (p.Arg182Gln) mutation can
be seen in affected individuals P1–P3 (II-
1, II-2 and II-3); there is no mutation in
unaffected sibling P4 (II-4).
(B) The genomic structure of isoform 1
(cytosolic) and isoform 2 (mitochondrial)
NFU1 is shown for individuals P1–P3 (II-
1, II-2, and II-3). The c.545G>A mutation
is identified. The normal alternate splicing
that creates the two isoforms from the
gDNA sequence is shown with solid lines,
and the effect of the mutation on the
splice site between exons 5 and 6 is
demonstrated with dashed lines, yielding
three possible transcripts.
(C) PCR amplification from individual P1
(II-1, NFU1 mutation), P5 (II-1 in Figure 3,
BOLA3 mutation), and control cDNA.
In the control and individual P5 cDNA,
two transcripts representing the cytosolic
and mitochondrial isoforms can be seen.
In individual P1, there is almost no full-
length mitochondrial NFU1, and two
smaller transcripts are present (a and b).
There is less cytosolic NFU1 in individual
P1, with one transcript variant visible (a).
The mutant transcripts a and b are all
identified in (A) and were all verified by
sequencing.
(D) Immunoblot of mitochondria showing
the mitochondrial isoform of NFU1 with
citrate synthase as a loading control.sequence coded in exon 1A. Isoform 1 (NM_015700.2)
contains exon 1B, and translation is predicted to start
from a downstream AUG start codon in exon 2 and
produce a protein that remains in the cytosol. The
c.545G>A mutation thus affects both the mitochondrial
and cytosolic isoforms of the protein, and is predicted to
result in an p.Arg182Gln substitution, but only if exon 6
is spliced correctly to exon 7. It is, however, adjacent to
the GU 50 splice donor in intron 6, and RT-PCR analysis
in Figure 2C shows that exon 6 is spliced out from the
majority of transcripts. In fact the full-length mitochon-
drial transcript is not detected by this analysis. We have
sequenced separate cloned RT-PCR transcripts of NFU1
from individuals P1–P3 (II-1, II-2, and II-3 in Figure 2) rep-
resenting cNFU1a (cytosolic transcript missing exon 6),
mNFU1 (mitochondrial transcript with c.545G>A muta-
tion), mNFU1a (missing exon 6), and mNFU1b (missing
exons 6 and 7). The only transcript that was not confirmed
by sequencing was cNFU1 containing the c.545G>Amuta-The American Journal of Human Getion. Figure 2D shows the NFU1
protein product in mitochondria
isolated from affected individuals P1
(II-1), P5 (II-1 in Figure 3), and control
fibroblasts. There is no immunode-
tectable mitochondrial NFU1 protein
in individual P1.Mutations in the coding regions of NFU1, the promoter,
or the intron/exon boundaries of the gene were not identi-
fied in the single affected individual from the second
family (individual P5, II-1 in Figure 3), suggesting another
gene defect in the same chromosomal region. Several
candidate genes were tested and were chosen on the basis
of chromosomal location, a high probability of mitochon-
drial import (determined with Mitoprot7), and tentative
roles in metabolism or gene regulation (genes sequenced
were AHSA2, BCS1L [MIM 603647], SMEK2 [MIM
610352], CCT4 [MIM 605142], SLC1A4 [MIM 600229],
SPR [MIM 182125], SFXN5, FLJ30838, FAM161A [MIM
613596], LOC647074, MDH1 [MIM 154200], RAB1A
[MIM 179508], and LOC388955). A homozygous single-
base-pair duplication (c.123dupA; p.Glu42Argfs*13) was
identified in exon 2 of BOLA3 (MIM 613183, 4.7 Mb
upstream of NFU1) in individual P5 (II-1 in Figure 3), re-
sulting in a frameshift and predicting a premature stop
codon (p.Glu42Argfs*13). The parents and an unaffectednetics 89, 486–495, October 7, 2011 489
Figure 3. Analysis of BOLA3 in Family 2
(A) Sequence chromatograms are shown for
gDNA regions of BOLA3. The single base pair
duplication (c.123dupA) can be seen in indi-
vidual P5 (II-1). The parents (I-1, I-2) and unaf-
fected sibling P6 (II-2) are all heterozygous. There
is no mutation in NFU1 mutant individual P1
(II-1 in Figure 2).
(B) The two isoforms of BOLA3 cDNA are shown
with the mutation seen in P5 (II-1) highlighted.sibling (individual P6, II-2 in Figure 3), were all heterozy-
gous carriers for the mutation. The mutation was not iden-
tified in seven different control samples or in the EST data-
base (68 BOLA3 ESTs).
The human protein BOLA3 is predicted to have a mito-
chondrial targeting sequence, and a 95% probability of
import into the mitochondria.7 Human BOLA3 has two
isoforms (NM_001035505.1 and NM_212552.2); isoform
2 lacks exon 3, which is present in isoform 1, resulting in
different stop codons in the two transcripts (Figure 3B).
Both isoforms are affected by the mutation in exon 2 in
P5 (II-1 in Figure 3), and the amount of full-length tran-
script for either isoform does not appear to be reduced
(data not shown). Respiratory chain complexes I, II, and
III all have components that contain [Fe-S] clusters. For
both families, several subunits of complex I (NDUFS1,
which contains [Fe-S]; NDUFV1, which contains [Fe-S];
NDUFS2; NDUFA9; and NDUFB8) were analyzed and all
showed a complete loss of protein except for NDUFS1,
which had a 20% reduction in the NFU1mutant compared
to citrate synthase and 40% reduction in the BOLA3
mutant (Figure 4). Because NFU1 and ISCU have the
same proposed role in [Fe-S] cluster synthesis, albeit in
parallel pathways, we thought it prudent to compare the490 The American Journal of Human Genetics 89, 486–495, October 7, 2011biochemical and clinical consequences of
both defects. In contrast to the NFU1 and
BOLA3 mutant fibroblasts, the ISCU mu-
tant individual has normal NFU1; complex
I NDUFS2, NDUFA9, and NDUFB8; and
complex III UQCRC1 protein levels.
However, complex III UQCRFS1, which
contains an [Fe-S] cluster, was severely
reduced in this individual (60% compared
to citrate synthase). In the NFU1 and
BOLA3 mutant individuals, complex II
subunit SDHA was reduced by 69% and
73%, respectively, as well as UQCRFS1
(70% and 76% reduction) and UQCRC1
subunits of complex III (22% and 60%
reduction), whereas cytochrome b expres-
sion was affected differently in the two
individuals (13% increase and 30% reduc-
tion) (Figure 4).
In contrast PDHc and OGDHc constit-
uent subunit proteins do not contain
[Fe-S] clusters, but those complexes showprofound enzyme deficiency.6 The common feature of
these enzymes is the requirement for covalently attached
lipoate on the E2 subunits of PDHc (dihydrolipoamide
transacetylase [DLAT]) and OGDHc (dihydrolipoyl trans-
succinylase [DLST] [MIM 126063]), and the E3BP subunit
of PDHc.
We used an antibody to lipoate to identify the lipoate
containing subunits of both PDHc and OGDHc complexes
in fibroblast cell mitochondria. Anti-lipoate failed to detect
the expected lipoylated E2 proteins of PDHc and OGDHc
in both families with multiple mitochondrial dysfunctions
syndrome (Figure 4). The individual with the NFU1 muta-
tion has a single weak band at a differentmolecular weight,
which could represent a modified form of lipoate. P5 (II-1
in Figure 3) showed no detectable lipoate labeling. We
attempted to improve the defective enzyme activities in
the affected fibroblasts by adding exogenous lipoate, but
no effect was seen on PDHc activity after three days of
culture in media supplemented with 30 mM lipoic acid.
To confirm the pathogenicity of the NFU1 and the
BOLA3 mutations, we constructed retroviral expression
vectors for both isoforms of each gene, transduced fibro-
blast cell lines, and tested for complementation of the bio-
chemical defect by immunoblot, BN-PAGE electrophoresis
Figure 4. Immunoblot Analysis of the Oxoacid Dehydrogenases
and Respiratory Chain Subunits in NFU1, BOLA3, and ISCU
Mutant Fibroblasts
Immunoblots of 25 mg fibroblast mitochondria were immunoblot-
ted with antibodies against NFU1, lipoate, complex I subunits
(NDUFS1, NDUFV1, NDUFS2, NDUFA9, and NDUFA8), complex
II subunit SDHA, complex III subunits (UQCRFS1, UQCRC1, and
CYTB), and citrate synthase (CS).(Figure 5), immunofluorescence (Figure 6), and PDHc
enzyme activity measurements (Figure 7). Interestingly,
the mitochondrial but not the cytosolic version of NFU1,
completely rescued the respiratory chain and oxoacid
dehydrogenase defects in immortalized fibroblasts from
individual P1 (II-1 in Figure 2). Similarly, only the longer
isoform of BOLA3 (BOLA3-1) restored all of the biochem-
ical abnormalities in individual P5 (II-1 in Figure 3). For
both defects, protein levels of complex I subunit NDUFA9,
complex II subunit SDHA, and lipoate were all restored to
normal levels (Figures 5A and 5C), as well as assembly of
the full complexes I and II (Figures 5B and 5D). PDHc
enzyme activity (both native and DCA-activated) was also
restored to control levels (Figure 7). Immunofluorescence
experiments in COS-7 cells and control fibroblasts (Fig-
ure 6A, a and b) confirmed that endogenous NFU1 mainly
localizes into mitochondria. In accordance with immuno-
blot results, only the overexpression of the mitochondrial
version of NFU1 is able to rescue the decreased level of
SDHA observed in individual P1 (Figure 6A, compare d to
c and e). Moreover, Figure 6B shows the long isoform of
BOLA3 (BOLA3.1) localized into mitochondria and the
short version (BOLA3.2) in the cytoplasm.The AmericDiscussion
We have identified a family with a mutation in NFU1,
which encodes an [Fe-S] cluster biogenesis protein. The
c.545G>A mutation causes splice site instability leading
to the production of several truncated transcripts and no
mitochondrial NFU1 protein product. We have also identi-
fied a family with a mutation in BOLA3, a previously un-
characterized gene that the present results suggest is also
involved in [Fe-S] cluster synthesis. How do these findings
fit with our knowledge of [Fe-S] cluster biogenesis?
NFU1 as an Alternate Scaffold for [Fe-S] Cluster
Biogenesis
[Fe-S] clusters function as the prosthetic groups of many
proteins essential for intermediary metabolism and oxida-
tive phosphorylation. They exist mainly as [2Fe-2S] and
[4Fe-4S] clusters and participate in electron transfer reac-
tions in which oxidation or reduction of oxygen or sulfur
is desirable.17 [Fe-S] clusters are essential components of
enzymes involved in the maturation of subunits of
complexes I, II, and III as well in the synthesis of the
enzyme-bound cofactor lipoate present in the 2-oxoacid
dehydrogenases. [Fe-S] clusters are constructed and assem-
bled into proteins in a series of complex biochemical reac-
tions that appear to run in two parallel pathways.17 The
process occurs in themitochondrial matrix with the export
of some clusters to form cytosolic and nuclear proteins
(Figure 1).
The role of NFU1 in [Fe-S] cluster biogenesis has been
deduced from its orthology to the bacterial protein NifU.
NFU1 and ISCU in eukaryotes both evolved from different
domains of NifU, a protein present in nitrogen-fixing
bacteria. ISCU is thought to function as a scaffold for the
assembly of [Fe-S] clusters, but the role of NFU1 is less clear.
Several roles for NFU1 have been hypothesized, two of
which are involved in [Fe-S] cluster biosynthesis. By
demonstrating the ability of NFU1 to assemble [4Fe-4S]
clusters and transfer them to apoproteins,16,18 it has been
suggested that NFU1 could function as an alternate scaf-
fold to ISCU for assembly of [Fe-S] proteins, thus providing
parallel pathways (Figure 1).17,19,20
The c.545G>A mutation results in truncated transcripts
for both mitochondrial and cytosolic NFU1 isoforms, and
therefore could affect both protein products. Mammalian
NFU1 is one of several [Fe-S] cluster genes (NFS1 [MIM
603485], ISCU, and NFU1) reported to have mitochondrial
and cytosolic isoforms. In the individuals reported here,
the c.545G>A mutation appears to be spliced out of virtu-
ally all of the transcribed forms of mitochondrial forms of
NFU1, resulting in barely detectable levels of the protein
(Figure 5A). Transfection of the cytosolic transcript does
result in a partial restoration of complex I NDUFA9 and
complex II SDHA subunit levels, but this appears to result
from a low level of expression of the mitochondrial iso-
form from this construct, probably because of readthrough
of the stop codon in exon 1B.an Journal of Human Genetics 89, 486–495, October 7, 2011 491
Figure 5. Rescue of the Biochemical Deficiencies in NFU1 and BOLA3 Mutant Fibroblasts by Retroviral Expression of the Wild-Type
cDNAs
(A) Immunoblot of control andmutant NFU1 fibroblast mitochondria transduced with constructs expressingmitochondrial or cytosolic
isoforms of NFU1were immunoblotted with antibodies against NFU1, lipoate, complex I subunit NDUFA9, complex II subunit SDHA,
and actin.
(B) BN-PAGE analysis of the same samples as in (A).
(C) Immunoblot of control and mutant BOLA3 fibroblast mitochondria transduced with constructs expressing the BOLA3-1 and
BOLA3-2 isoforms were immunoblotted with antibodies against NFU1, lipoate, complex I subunit NDUFA9, complex II subunit
SDHA, and actin.
(D) BN-PAGE analysis of the same samples as in (C).Inference of the Role of BOLA3 in [Fe-S] Cluster
Synthesis
Mammalian BOLA3 belongs to a BolA-like family of
proteins that is conserved from prokaryotes to eukaryotes.
They were originally thought to be DNA-binding proteins
(based on the presence of a helix-turn-helix motif), which
create a round morphology in Escherichia coli cells when
overexpressed.21 They have also been shown to be ex-
pressed under stress situations such as carbon starvation
and oxidative stress.22
Little is known about the function of human BOLA3, but
predictions can be made from the roles of ortholog
proteins. BolA family members have been postulated to
act as reductases, interacting with the mono-thiol glutare-
doxin family.23 Genome-wide yeast two-hybrid studies
have shown a physical interaction between cytosolic
monothiol glutaredoxins (Grx) and BolA-like proteins in
Saccharomyces cerevisiae and Drosophila melanogaster.24,25
In several genomes, genes encoding Grx and BolA-like
proteins lie physically next to each other, and the two
protein families show co-occurrence in organisms because
only those that express BolA proteins possess monothiol
Grx proteins.23 It is possible that BOLA3 is interacting
with glutaredoxin 5, which along with several chaperones492 The American Journal of Human Genetics 89, 486–495, Octoberis involved in inserting [2Fe-2S] and [4Fe-4S] clusters into
apoproteins (Figure 1).
Transfection of both isoforms of BOLA3 into deficient
fibroblasts showed that only isoform 1 can restore protein
steady-state levels, respiratory chain complex assembly,
and enzyme activities (Figures 5B, 5D, and 7). The role of
the shorter isoform is unknown. Immunofluorescence
results show this isoform, but not BOLA3-2, localizes to
mitochondria (Figure 6B).What is the nature of the 2-oxoa-
cid dehydrogenase enzyme c defect in the mutant NFU1
and BOLA3 individuals?
Mutation of NFU1 would be expected to interfere with
the pathway of [Fe-S] cluster synthesis resulting in
a decrease in the assembly and activity of complexes I, II,
and III. This does not however explain the profound deficit
in PDHc activity (<10% control), in the face of apparently
normal assembly of the protein components of PDH.6 The
lack of immunoreactive lipoate in the PDH or 2OGDH
complexes, however, is compelling and suggests that
both NFU1 and BOLA3 are necessary for lipoate synthesis.
That these are candidates for defects in lipoate synthesis
is evident from work on yeast in which elimination of
cysteine desulphurase (NFS1), iron sulfur assembly protein
(ISA1), or IBA57 results in an inability to produce lipoate7, 2011
Figure 6. Immunofluorescence analysis of Fibroblast Cells
Transduced with Retroviral Constructs Expressing the Cytosolic
and Mitochondrial Versions of NFU1 and the Two Isoforms of
BOLA3
(A) SDHA was used as a mitochondrial marker and as a marker of
the respiratory chain defect. The predicted mitochondrial isoform
of NFU1 localizes to mitochondria, and expression of the cDNA
rescues the SDHA defect in individual P1 (II-1 in Figure 1) cells.
The cytosolic isoform shows diffuse staining in mutant fibroblasts
and does not rescue the complex II defect.
(B) BOLA3-1HA rescues the complex II defect of individual P5 and
localizes to mitochondria, but BOLA3-2HA shows diffuse staining
and does not rescue the defect.
Figure 7. Pyruvate Dehydrogenase Enzyme Activities for
Control and Mutant NFU1 and BOLA3 Fibroblasts
Native and DCA-activated PDHc enzyme activities were deter-
mined for control and mutant NFU1 fibroblast mitochondria
transfected with mitochondrial and cytosolic transcripts of
NFU1, and control and mutant BOLA3 fibroblast mitochondria
transfected with BOLA3-1 and BOLA3-2 isoforms. Data are repre-
sented as mean5 SEM for four separate enzyme measurements.or lipoylated proteins.26,27 The E2 protein of PDHc,
2OGDH, and BCKADHc is initially octanoylated on lysine
residues by lipoyl transferase 2 (LIPT2) in the biosynthetic
pathway (Figure 1) or lipoyl transferase 1 (LIPT1) in the
salvage pathway. This is subsequently transformed to lip-The Americoate by the addition of two sulfur atoms in a reaction cata-
lyzed by lipoic acid synthase (LIAS), an enzyme possessing
two [4Fe-4S] clusters with unusual cysteine-containing
motifs CX3CX2C and CX4CX5C in the protein se-
quence.28–30 It is known that the E2 protein of the PDHc
runs at a different mobility on SDS-PAGE gels when lipoy-
lated (72 kDa) compared to its unlipoylated mobility
(55 kDa). The mobility observed in individual P1 (II-1 in
Figure 2) for the PDHc-E2 is less than 72 kDa, suggesting
that the mobility has been altered by octanoylation. The
intactness of the PDHc-E2 enzyme function is illustrated
by the fact that fibroblasts from both affected individuals
possess normal dihydrolipoyl transacetylase activity when
measured by acetylation of reduced lipoic acid by acetyl
CoA. However, because this assay is carried out with added
reduced lipoic acid, the enzyme does not require enzyme-
bound lipoate to function. Nevertheless, the activity of
both PDHc and OGDHc in P5 the unsupplemented
complex is greatly reduced, and there is virtually no such
activity in individual P1. We hypothesize that the loss
of mNFU1 and BOLA3-1 in these individuals might be
specifically affecting thematuration of lipoic acid synthase,
an [Fe-S] cluster protein, which in turn will impact the
enzyme activities of PDHc and OGDHc (Figure 7).
WhyDo NFU1 and BOLA3Mutations Have a Different
Phenotype from that Seen with ISCU Mutations?
Themost profound differences between the three classes of
defect is a loss of aconitase protein13 and enzyme activityan Journal of Human Genetics 89, 486–495, October 7, 2011 493
in ISCU mutants and lipoate abnormalities in NFU1/
BOLA3 mutants; there is an indication of less affected
complex I in the ISCU mutant. Mitochondrial aconitase
enzyme levels in the NFU1/BOLA3 mutant individuals
were normal (Table 1) as were protein levels (data not
shown). This suggests a divergence between the roles of
NFU1/BOLA3 and ISCU, with NFU1 and BOLA3 special-
izing in proteins destined to become involved in the
lipoate pathway. It had previously been suggested that
aconitase-like proteins and radical S-adenosyl methionine
(SAM) proteins (such as lipoate synthase) are assembled
in the same pathway.26 Recent work shows that many
more [Fe-S] cluster-containing proteins appear to have
specific maturation or assembly factors, for example,
human IND1 for complex I proteins,31,32 and E. coli ErpA,
essential for an [Fe-S] protein involved in isoprenoid
biosynthesis.33 It is therefore likely that the roles of NFU1
and BOLA3 in eukaryotes are not as simple as has so far
been hypothesized with more specialization than previ-
ously thought. ISCU assembled [Fe-S] clusters appear to
be preferentially channeled to aconitase and complex II,
whereas NFU1- (and BOLA3-) dependent assembled clus-
ters are more directed to complex I and lipoate synthesis.
We conclude that in humans there are parallel pathways
for synthesis of [Fe-S] clusters, and there is a bias in each
pathway for maturation of certain target proteins. How
this is achieved will be the subject of further research.Supplemental Data
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